<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
         xmlns="http://purl.org/rss/1.0/"
         xmlns:admin="http://webns.net/mvcb/"
         xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
         xmlns:dc="http://purl.org/dc/elements/1.1/"
         xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
  <channel rdf:about="https://hstalks.com/rss/by-category/754/">
    <title>Pharmaceutical Sciences</title>
    <link>https://hstalks.com/category/754/pharmaceutical-sciences/?biosci</link>
    <description>New and updated series &amp; talks on Pharmaceutical Sciences from HSTalks&#x27; Biomedical &amp; Life Sciences Collection.</description>
    <admin:generatorAgent rdf:resource="http://www.hstalks.com/" />
    <admin:errorReportsTo rdf:resource="mailto:info@hstalks.com" />
    <sy:updatePeriod>daily</sy:updatePeriod>
    <sy:updateFrequency>1</sy:updateFrequency>
    <sy:updateBase>2006-01-01T12:00+00:00</sy:updateBase>
    <dc:publisher>Henry Stewart Talks</dc:publisher>
    <dc:language>en</dc:language>
    <dc:rights>© Copyright Henry Stewart Talks Ltd.</dc:rights>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
    <prism:copyright>© Copyright Henry Stewart Talks Ltd.</prism:copyright>
    <items>
      <rdf:Seq>
      <rdf:li resource="https://hstalks.com/playlist/1941/regulatory-ich-guidelines-with-nonclinical-impact/?biosci" />
      <rdf:li resource="https://hstalks.com/t/17614/m4-common-technical-dossier/?biosci" />
      <rdf:li resource="https://hstalks.com/t/17251/advanced-therapies-in-an-evolving-regulatory-and-a/?biosci" />
      <rdf:li resource="https://hstalks.com/t/18241/nonclinical-safety-testing-of-human-pharmaceutical/?biosci" />
      <rdf:li resource="https://hstalks.com/t/17086/ich-s3a-and-s3b-toxicokinetics-and-pharmacokinetic/?biosci" />
      <rdf:li resource="https://hstalks.com/t/16690/muscarinic-acetylcholine-receptor-modulation-in-ne/?biosci" />
      <rdf:li resource="https://hstalks.com/t/16888/use-of-cholera-vaccine-in-bangladesh-success-and-s/?biosci" />
      <rdf:li resource="https://hstalks.com/t/19860/receptor-types-and-drug-targets/?biosci" />
      <rdf:li resource="https://hstalks.com/t/18549/antihypertensives/?biosci" />
      <rdf:li resource="https://hstalks.com/t/14974/virtual-screening-personal-reflections-and-future-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/15898/ai-based-regulatory-compliance-in-drug-development/?biosci" />
      <rdf:li resource="https://hstalks.com/t/15040/cochrane-databases-history-utility-1/?biosci" />
      <rdf:li resource="https://hstalks.com/t/15041/cochrane-databases-history-utility-2/?biosci" />
      <rdf:li resource="https://hstalks.com/t/16624/what-i-do-director-of-biostatistics/?biosci" />
      <rdf:li resource="https://hstalks.com/t/18548/dose-response-curves-and-therapeutic-index/?biosci" />
      <rdf:li resource="https://hstalks.com/t/14809/next-generation-microneedle-technologies-for-drug-/?biosci" />
      
      </rdf:Seq>
    </items>
  </channel>

  <item rdf:about="https://hstalks.com/playlist/1941/regulatory-ich-guidelines-with-nonclinical-impact/?biosci">
    <title>Regulatory ICH Guidelines with Nonclinical Impact [series]</title>
    <link>https://hstalks.com/playlist/1941/regulatory-ich-guidelines-with-nonclinical-impact/?biosci</link>
    <description>M4 Common Technical Dossier - M3 Nonclinical Requirements for Clinical Trials, First-in-Human - S1A/C Carcinogenicity Studies: When are they Needed/ Dose Selection - S1B Testing Carcinogenic Potential of Human Pharmaceuticals, Transgenic Models - S6 Preclinical Requirements for Biotechnology-derived Products - S7 Safety Pharmacology - S8 Immunotoxicity - S11 Juvenile Toxicity Testing - 1B(R1) Testing Carcinogenic Potential of Human Pharmaceuticals Approach - S2 Genotoxicity - S3 Pharmacokinetics - S4 Chronic Toxicity- S5 Reproductive Toxicity Testing - S9 Testing of anticancer compounds - S10 Photosafety - S12 Nonclinical Safety Testing of Gene Therapy</description>
    <dc:title>Regulatory ICH Guidelines with Nonclinical Impact</dc:title>
    <dc:creator>Dr. Jan Willem van der Laan</dc:creator>
    
    
    <dc:subject>M4 Common Technical Dossier, M3 Nonclinical Requirements for Clinical Trials, First-in-Human, S1A/C Carcinogenicity Studies: When are they Needed/ Dose Selection, S1B Testing Carcinogenic Potential of Human Pharmaceuticals, Transgenic Models, S6 Preclinical Requirements for Biotechnology-derived Products, S7 Safety Pharmacology, S8 Immunotoxicity, S11 Juvenile Toxicity Testing, 1B(R1) Testing Carcinogenic Potential of Human Pharmaceuticals Approach, S2 Genotoxicity, S3 Pharmacokinetics, S4 Chronic Toxicity- S5 Reproductive Toxicity Testing, S9 Testing of anticancer compounds, S10 Photosafety, S12 Nonclinical Safety Testing of Gene Therapy</dc:subject>
    <dc:date>2026-03-31</dc:date>
    <prism:publicationDate>2026-03-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/17614/m4-common-technical-dossier/?biosci">
    <title>M4 common technical dossier [17 mins] </title>
    <link>https://hstalks.com/t/17614/m4-common-technical-dossier/?biosci</link>
    <description>CTD triangle - Nonclinical overview - Nonclinical written summaries - Assessment reports - Appendices</description>
    <dc:title>M4 common technical dossier</dc:title>
    
    <dc:creator>Dr. Jan Willem van der Laan</dc:creator>
    
    <dc:subject>CTD triangle, Nonclinical overview, Nonclinical written summaries, Assessment reports, Appendices</dc:subject>
    <dc:date>2026-03-31</dc:date>
    <prism:publicationDate>2026-03-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/17251/advanced-therapies-in-an-evolving-regulatory-and-a/?biosci">
    <title>Advanced therapies in an evolving regulatory and access environment [19 mins] </title>
    <link>https://hstalks.com/t/17251/advanced-therapies-in-an-evolving-regulatory-and-a/?biosci</link>
    <description>Pharma legislation - ATMPs situation in EU - Role of academia in development of advanced therapies - Strategies for translating therapies from Idea to Patient Care - Manufacturing Do’s and Don’ts</description>
    <dc:title>Advanced therapies in an evolving regulatory and access environment</dc:title>
    
    <dc:creator>Dr. Ana Hidalgo-Simon</dc:creator>
    
    <dc:subject>Pharma legislation, ATMPs situation in EU, Role of academia in development of advanced therapies, Strategies for translating therapies from Idea to Patient Care, Manufacturing Do’s and Don’ts</dc:subject>
    <dc:date>2026-03-31</dc:date>
    <prism:publicationDate>2026-03-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/18241/nonclinical-safety-testing-of-human-pharmaceutical/?biosci">
    <title>Nonclinical safety testing of human pharmaceuticals in relation to clinical development [29 mins] </title>
    <link>https://hstalks.com/t/18241/nonclinical-safety-testing-of-human-pharmaceutical/?biosci</link>
    <description>ICH participants and ICH safety topics - Benefit-risk assessment - ICH M3: Mother of all guidelines - Guidance history on first-in-human (FIH) starting dose - ICH S7A: Safety pharmacology studies - S7B: Non-clinical testing strategy - Genotoxicity testing - ICH S4: Single and repeated dose toxicity studies</description>
    <dc:title>Nonclinical safety testing of human pharmaceuticals in relation to clinical development</dc:title>
    
    <dc:creator>Dr. Jan Willem van der Laan</dc:creator>
    
    <dc:subject>ICH participants and ICH safety topics, Benefit-risk assessment, ICH M3: Mother of all guidelines, Guidance history on first-in-human (FIH) starting dose, ICH S7A: Safety pharmacology studies, S7B: Non-clinical testing strategy, Genotoxicity testing, ICH S4: Single and repeated dose toxicity studies</dc:subject>
    <dc:date>2026-03-31</dc:date>
    <prism:publicationDate>2026-03-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/17086/ich-s3a-and-s3b-toxicokinetics-and-pharmacokinetic/?biosci">
    <title>ICH S3A and S3B toxicokinetics and pharmacokinetics [11 mins] </title>
    <link>https://hstalks.com/t/17086/ich-s3a-and-s3b-toxicokinetics-and-pharmacokinetic/?biosci</link>
    <description>ICH establishment &amp; guidelines - Pharmacokinetics - Toxicokinetics - Microsampling</description>
    <dc:title>ICH S3A and S3B toxicokinetics and pharmacokinetics</dc:title>
    
    <dc:creator>Dr. David R. Jones</dc:creator>
    
    <dc:subject>ICH establishment &amp; guidelines, Pharmacokinetics, Toxicokinetics, Microsampling</dc:subject>
    <dc:date>2026-03-31</dc:date>
    <prism:publicationDate>2026-03-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/16690/muscarinic-acetylcholine-receptor-modulation-in-ne/?biosci">
    <title>Muscarinic acetylcholine receptor modulation in neurological diseases [20 mins] </title>
    <link>https://hstalks.com/t/16690/muscarinic-acetylcholine-receptor-modulation-in-ne/?biosci</link>
    <description>Muscarinic acetylcholine receptors - Neurological drug discovery - Schizophrenia and Alzheimer’s disease - Structure-based drug design - Allosteric GPCR modulation</description>
    <dc:title>Muscarinic acetylcholine receptor modulation in neurological diseases</dc:title>
    
    <dc:creator>Prof. Andrew B. Tobin</dc:creator>
    
    <dc:subject>Muscarinic acetylcholine receptors, Neurological drug discovery, Schizophrenia and Alzheimer’s disease, Structure-based drug design, Allosteric GPCR modulation</dc:subject>
    <dc:date>2026-03-31</dc:date>
    <prism:publicationDate>2026-03-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/16888/use-of-cholera-vaccine-in-bangladesh-success-and-s/?biosci">
    <title>Use of cholera vaccine in Bangladesh: success and struggles [32 mins] </title>
    <link>https://hstalks.com/t/16888/use-of-cholera-vaccine-in-bangladesh-success-and-s/?biosci</link>
    <description>Cholera vaccination stats of Bangladesh - Vaccine research and development for cholera in Bangladesh - Bangladesh cholera vaccination for Rohingya refugees - Cholera sources - Cholera prevention - Cholera strains</description>
    <dc:title>Use of cholera vaccine in Bangladesh: success and struggles</dc:title>
    
    <dc:creator>Dr. Firdausi Qadri</dc:creator>
    
    <dc:subject>Cholera vaccination stats of Bangladesh, Vaccine research and development for cholera in Bangladesh, Bangladesh cholera vaccination for Rohingya refugees, Cholera sources, Cholera prevention, Cholera strains</dc:subject>
    <dc:date>2026-03-31</dc:date>
    <prism:publicationDate>2026-03-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/19860/receptor-types-and-drug-targets/?biosci">
    <title>Receptor types and drug targets [4 mins] </title>
    <link>https://hstalks.com/t/19860/receptor-types-and-drug-targets/?biosci</link>
    <description>Receptor types and classes - Drug-receptor interaction mechanisms - Major drug targets - Target selectivity and side effects - Roles of agonists, antagonists, modulators - Genetic variability in personalized medicine</description>
    <dc:title>Receptor types and drug targets</dc:title>
    
    
    <dc:subject>Receptor types and classes, Drug-receptor interaction mechanisms, Major drug targets, Target selectivity and side effects, Roles of agonists, antagonists, modulators, Genetic variability in personalized medicine</dc:subject>
    <dc:date>2026-03-31</dc:date>
    <prism:publicationDate>2026-03-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/18549/antihypertensives/?biosci">
    <title>Antihypertensives [5 mins] </title>
    <link>https://hstalks.com/t/18549/antihypertensives/?biosci</link>
    <description>Hypertension management for CV risk - Antihypertensive drug classes and mechanisms - Antihypertensive side effects and prescribing - Therapy tailored by comorbidity and ethnicity - Monitoring and patient involvement - Antihypertensive combination therapy - Special considerations in diabetes and CKD</description>
    <dc:title>Antihypertensives</dc:title>
    
    
    <dc:subject>Hypertension management for CV risk, Antihypertensive drug classes and mechanisms, Antihypertensive side effects and prescribing, Therapy tailored by comorbidity and ethnicity, Monitoring and patient involvement, Antihypertensive combination therapy, Special considerations in diabetes and CKD</dc:subject>
    <dc:date>2026-02-26</dc:date>
    <prism:publicationDate>2026-02-26</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/14974/virtual-screening-personal-reflections-and-future-/?biosci">
    <title>Virtual screening: personal reflections and future directions [45 mins] </title>
    <link>https://hstalks.com/t/14974/virtual-screening-personal-reflections-and-future-/?biosci</link>
    <description>Virtual Screening - Structure-based vs. ligand-based - Virtual screening case studies - Cryo-electron microscopy - AI: docking and scoring</description>
    <dc:title>Virtual screening: personal reflections and future directions</dc:title>
    
    <dc:creator>Dr. David E. Clark</dc:creator>
    
    <dc:subject>Virtual Screening, Structure-based vs. ligand-based, Virtual screening case studies, Cryo-electron microscopy, AI: docking and scoring</dc:subject>
    <dc:date>2026-02-26</dc:date>
    <prism:publicationDate>2026-02-26</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/15898/ai-based-regulatory-compliance-in-drug-development/?biosci">
    <title>AI-based regulatory compliance in drug development [38 mins] </title>
    <link>https://hstalks.com/t/15898/ai-based-regulatory-compliance-in-drug-development/?biosci</link>
    <description>Artificial intelligence (AI) - Regulatory frameworks - Data heterogeneity - Ethical and transparency concerns - Data-driven decision making - Algorithmic transparency and interpretability - Regulatory innovation and technological integration</description>
    <dc:title>AI-based regulatory compliance in drug development</dc:title>
    
    <dc:creator>Dr. Antonio Pesqueira</dc:creator>
    
    <dc:subject>Artificial intelligence (AI), Regulatory frameworks, Data heterogeneity, Ethical and transparency concerns, Data-driven decision making, Algorithmic transparency and interpretability, Regulatory innovation and technological integration</dc:subject>
    <dc:date>2026-02-26</dc:date>
    <prism:publicationDate>2026-02-26</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/15040/cochrane-databases-history-utility-1/?biosci">
    <title>Cochrane databases: history &amp; utility 1 [10 mins] </title>
    <link>https://hstalks.com/t/15040/cochrane-databases-history-utility-1/?biosci</link>
    <description>Cochrane history, organization and structure - Cochrane Database of Systematic Reviews (CDSR) - Types of Cochrane reviews - Cochrane Central Register of Controlled Trials (CENTRAL) - The creation and maintenance of CENTRAL</description>
    <dc:title>Cochrane databases: history &amp; utility 1</dc:title>
    
    <dc:creator>Dr. Riaz Qureshi</dc:creator>
    
    <dc:subject>Cochrane history, organization and structure, Cochrane Database of Systematic Reviews (CDSR), Types of Cochrane reviews, Cochrane Central Register of Controlled Trials (CENTRAL), The creation and maintenance of CENTRAL</dc:subject>
    <dc:date>2026-02-26</dc:date>
    <prism:publicationDate>2026-02-26</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/15041/cochrane-databases-history-utility-2/?biosci">
    <title>Cochrane databases: history &amp; utility 2 [10 mins] </title>
    <link>https://hstalks.com/t/15041/cochrane-databases-history-utility-2/?biosci</link>
    <description>Searching CDSR and CENTRAL - Different search options in Cochrane database - Searching the CDSR: Pro-tips - Online training and interactive learning from Cochrane - Cochrane crowd - Cochrane handbook</description>
    <dc:title>Cochrane databases: history &amp; utility 2</dc:title>
    
    <dc:creator>Dr. Riaz Qureshi</dc:creator>
    
    <dc:subject>Searching CDSR and CENTRAL, Different search options in Cochrane database, Searching the CDSR: Pro-tips, Online training and interactive learning from Cochrane, Cochrane crowd, Cochrane handbook</dc:subject>
    <dc:date>2026-02-26</dc:date>
    <prism:publicationDate>2026-02-26</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/16624/what-i-do-director-of-biostatistics/?biosci">
    <title>What I do: director of biostatistics [35 mins] </title>
    <link>https://hstalks.com/t/16624/what-i-do-director-of-biostatistics/?biosci</link>
    <description>Clinical trial design - Biostatistics - Statistical analysis - Real-world evidence - Patient-reported outcomes -  Gene therapy - Regulatory submissions - Data modelling</description>
    <dc:title>What I do: director of biostatistics</dc:title>
    
    <dc:creator>Dr. Avery McIntosh</dc:creator>
    
    <dc:subject>Clinical trial design, Biostatistics, Statistical analysis, Real-world evidence, Patient-reported outcomes, Gene therapy, Regulatory submissions, Data modelling</dc:subject>
    <dc:date>2026-02-26</dc:date>
    <prism:publicationDate>2026-02-26</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/18548/dose-response-curves-and-therapeutic-index/?biosci">
    <title>Dose-response curves and therapeutic index [4 mins] </title>
    <link>https://hstalks.com/t/18548/dose-response-curves-and-therapeutic-index/?biosci</link>
    <description>Dose-response curves - Potency and efficacy - EC50 and LD50 - Therapeutic index - Patient factors in drug response</description>
    <dc:title>Dose-response curves and therapeutic index</dc:title>
    
    
    <dc:subject>Dose-response curves, Potency and efficacy, EC50 and LD50, Therapeutic index, Patient factors in drug response</dc:subject>
    <dc:date>2026-02-26</dc:date>
    <prism:publicationDate>2026-02-26</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/14809/next-generation-microneedle-technologies-for-drug-/?biosci">
    <title>Next generation microneedle technologies for drug &amp; vaccine delivery [59 mins] </title>
    <link>https://hstalks.com/t/14809/next-generation-microneedle-technologies-for-drug-/?biosci</link>
    <description></description>
    <dc:title>Next generation microneedle technologies for drug &amp; vaccine delivery</dc:title>
    
    <dc:creator>Prof. Ryan F. Donnelly</dc:creator>
    
    <dc:subject></dc:subject>
    <dc:date>2026-02-24</dc:date>
    <prism:publicationDate>2026-02-24</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

</rdf:RDF>
